A Phase IV Enhanced Safety Surveillance Study of ACAM2000® in Military Personnel

Conditions:		Smallpox
Purpose:		This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: - To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in temporal association with ACAM2000® vaccination. Secondary Objectives: - To evaluate the rates of cardiovascular adverse events in temporal association with ACAM2000® vaccination. - To evaluate the rates of neurological adverse events in temporal association with ACAM2000® vaccination.
Study Summary:		The Armed Forces Health Surveillance Activity (AFHSA) will perform comprehensive health surveillance through the operation of the Defense Medical Surveillance System (DMSS). Demographic and medical information gathered within monthly reports from the DMSS will be collected from approximately 100,000 to 200,000 military Service Members who received the ACAM2000® smallpox vaccine.
Criteria:		Inclusion Criteria : - Male and female military personnel >= 17 years of age. - Have received the ACAM2000® smallpox vaccine. Exclusion Criteria : - Not applicable.
NCT ID:		NCT00927719
Primary Contact:		Study Director Medical Director Sanofi Pasteur Inc Public Registry Sanofi Pasteur Email: RegistryContactUs@sanofipasteur.com
Backup Contact:		N/A
Location Contact:		Ft Campbell, Kentucky 42223 United States *There is no listed contact information for this specific location.* Site Status: Recruiting

Data Source:		ClinicalTrials.gov
Date Processed:		May 23, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.